FDA Warns Providers Not to Use Any NECC Products

The FDA has warned healthcare providers to cease use of any products manufactured at the New England Compounding Center in Framingham, Mass., according to an AHA News Now report.

Advertisement

 

Sign up for our FREE E-Weekly for more coverage like this sent to your inbox!

The alert comes after the FDA determined that two additional drugs, triamcinolone acetonide and cardioplegic solution, from the compounding center may be contaminated. A federal/state investigation is ongoing regarding contaminated steroid injections that led to an outbreak of meningitis, claiming 15 lives.

More Articles on Patient Safety:

7 Strategies for Collaboration and Safety in the Operating Room

8 Points of Survival for Surgery Centers After ACOs

Study: Simulation Training Needed to Boost Patient Safety, Operative Performance

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Uncategorized

Advertisement

Comments are closed.